Abstracts tagged "monoclonal antibodies and scleroderma"

Abstract Number: 692 • ACR/ARHP Annual Meeting 2012
A Phase 1 Multicenter, Open-Label Study of MEDI-546, a Human Anti-Type I Interferon Receptor Monoclonal Antibody, in Adults with Scleroderma
Avram Z. Goldberg¹, Thomas D. Geppert², Elena Schiopu³, Tracy M. Frech⁴, Vivien M. Hsu⁵, Robert W. Simms⁶, Stanford L. Peng⁷, Yihong Yao⁸, Nairouz Elgeioushi⁹, Bing Wang¹⁰, Linda Chang¹¹ and Stephen Yoo¹², ¹Div of Rheumatology, North Shore-LIJ Health System, Lake Success, NY, ²Metroplex Clinical Research Center, LLC, Dallas, TX, ³Rheumatology/Internal Medicine, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁵Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷Department of Rheumatology, Benaroya Research Institute at Virginia Mason Medical Center, Seattle, WA, ⁸Translational Sciences, MedImmune, Gaithersburg, MD, ⁹Medical Biostatistics, MedImmune, Gaithersburg, MD, ¹⁰Clinical Pharmacology and DMPK, Medimmune, Mountain View, CA, ¹¹Translational Sciences, MedImmune, Hayward, CA, ¹²Clinical Development, MedImmune, Gaithersburg, MD
Background/Purpose: Type I interferons (IFNs) have been implicated in the pathogenesis of scleroderma. This phase 1 study evaluated safety, pharmacokinetics (PK), pharmacodynamics, and immunogenicity of…